KB-1365

LM-305-hIgG1

Home » Antibody » LM-305-hIgG1

Background

LM-305 is composed of an anti-GPRC5D monoclonal antibody (mAb), coupled with a protease-degradable linker and a cytotoxic payload known as monomethyl auristatin E (MMAE). This innovative formulation positions LM-305 as a prospective first-in-class ADC (Antibody-Drug Conjugate) targeting GPRC5D. With its unique design and targeting specificity, LM-305 emerges as a promising therapeutic avenue. It signifies a potential breakthrough in offering a novel treatment modality for individuals contending with relapsed/refractory conditions.

Specifications

Catalog Number:
KB-1365
Cell Line Name:
LM-305-hIgG1
Price:
0
Host Cell Line:
EXPI-CHO
Target:
GPRC5D
Species Reactivity:
Human
Application:
ELISA
Purification Method:
Affinity purified
Concentration:
>2mg/mL
Purity:
>95% by SDS-PAGE and SEC-HPLC
Endotoxin Level:
<0.5 EU/mg as determined by the LAL method
Sterility:
0.2¦Ìm filtered
Formulation:
20mM sodium citrate,150mM NaCl, pH5.5
Storage:
Stable for twelve months from date of receipt when stored at -20¡ãC to -80¡ãC; Stored at 2-8¡ãC for one month without detectable loss of activity.
Bio Safety Level:
1
Validation:
SDS-PAGE | SEC-HPLC | ELISA

References

1. GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells DOI: 10.1126/scitranslmed.aau7746. 2. Joshua Li, et al. The Molecule Pages database. Nature. 2002.
Please enable JavaScript in your browser to complete this form.